WallStSmart
BHVN

Biohaven Ltd.

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$13.43
-2.47% today

Updated 2026-07-29

Market cap
$2.34B
P/E ratio
P/S ratio
EPS (TTM)
$-5.57
Dividend yield
52W range
$7 – $19
Volume
3.1M

WallStSmart proprietary scores

25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.0
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-11.1
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target
$22.75
+69.40%
12-Month target
Intrinsic (DCF)
Margin of safety
4 Strong Buy10 Buy4 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -11.11 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-149.92M
- Debt/equity 2.21x — high leverage

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-570.28M$-408.17M$-846.42M$-738.82M$-130.53M
EPS$-5.57
Free cash flow$-338.76M$-334.77M$-586.50M$-610.15M$-149.92M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
BHVN$2.34B254.33.05.04.0Avoid
LLY$1.02T7610.010.04.36.0Strong Buy
JNJ$615.36B574.78.54.36.0Buy
ABBV$447.53B634.08.04.75.0-78.83%Buy
UNH$391.69B627.35.54.06.0-30.51%Buy
MRK$307.25B503.38.02.75.0-62.28%Hold

Smart narrative

Biohaven Ltd. trades at $13.43. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.11, it sits in the distress.

Frequently asked questions

What is Biohaven Ltd.'s stock price?

Biohaven Ltd. (BHVN) trades at $13.43.

Is Biohaven Ltd. overvalued?

Biohaven Ltd. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Biohaven Ltd. (BHVN)?

The 12-month analyst consensus target is $22.75, about 69.4% above the current $13.43. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Biohaven Ltd.'s Altman Z-Score is -11.11, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD

Quick metrics

P/S ratio
ROE-500.14%
Beta3.14
50D MA$12.44
200D MA$11.65
Shares out0.15B
Float0.12B
Short ratio
Avg volume3.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years